Indian drug maker, Dr Reddy's Laboratories Ltd, has announced that it has launched Reddy-Lenalidomide, a generic equivalent to Revlimid (lenalidomide) capsules in Canada.
The firm said that the launch came after the drug was approved by Health Canada. Reddy-Lenalidomide is claimed to be one of the first generic medications of its kind to be launched in Canada. It is used to treat patients with transfusion-dependent anaemia due to Low or lntermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality. Approval for the drug was provided based on red blood cell transfusion independence response rates. However, overall survival benefit has not been demonstrated.
Reddy-Lenalidomide can also be administered in combination with dexamethasone in multiple myeloma patients who are not eligible for stem cell transplant.
Kazia Therapeutics' paxalisib receives Orphan Drug Designation from FDAQ
Dr. Reddy's Laboratories Launches Pemetrexed for Injection USP, in the US Market
Accord Healthcare introduces Pemetrexed Lyo. Injection to range of chemotherapy drugs
Astellas receives unfavourable decision in LEXISCAN(R) 0.4mg/mL US patent trial
Famotidine (Pepcid) Activates the Vagus Nerve to Reduce Cytokine Storm in COVID-19, New Study Shows